Antihypertensive drugs and fibrinolytic function

Area of Science:

• Cardiovascular Pharmacology
• Hemostasis and Thrombosis

Background:

• Hypertension is linked to impaired fibrinolysis, indicated by elevated plasminogen activator inhibitor type 1 (PAI-1) and reduced tissue plasminogen activator (t-PA) activity.
• This prothrombotic state may contribute to atherosclerosis and suboptimal outcomes with antihypertensive treatments.
• Existing literature suggests varying effects of antihypertensive drugs on fibrinolysis.

Purpose of the Study:

• To review the influence of different antihypertensive drug classes on the fibrinolytic system.
• To explore the mechanisms behind these effects and the potential benefits of combination therapy.

Main Methods:

• Literature review of studies investigating the effects of diuretics, beta-blockers, ACE inhibitors, calcium channel blockers, and ARBs on fibrinolysis markers (PAI-1 and t-PA).
• Analysis of proposed mechanisms for drug-induced changes in fibrinolysis.
• Evaluation of data on combination therapies, specifically ACE inhibitors with CCBs.

Main Results:

• ACE inhibitors generally improve fibrinolysis by reducing PAI-1 levels.
• Calcium channel blockers have been reported to increase t-PA activity.
• Combination therapy with ACE inhibitors and CCBs shows a synergistic positive impact on fibrinolysis, decreasing PAI-1 and increasing t-PA.

Conclusions:

• ACE inhibitors positively influence fibrinolysis via angiotensin II inhibition, bradykinin preservation, and improved insulin sensitivity.
• CCBs may enhance t-PA activity through direct vascular endothelium actions.
• Combined ACE inhibitor and CCB therapy offers superior improvement in fibrinolytic balance, supporting their use in hypertension management.